Fig. 1: Circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels in a cohort of SMA patients treated at the pre-symptomatic stage with onasemnogene abeparvovec. | Gene Therapy

Fig. 1: Circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels in a cohort of SMA patients treated at the pre-symptomatic stage with onasemnogene abeparvovec.

From: Early life safety profiling of gene therapy for spinal muscular atrophy

Fig. 1

A–H Cohort receiving monotherapy. Blue line indicates the day of injection. Colored background area indicates normal concentrations expected in sex-matched controls.

Back to article page